Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. The approval of Emrosi is supported by positive data from Journey Medical's two Phase 3 clinical trials.
Journey Medical said it is completing the manufacturing of Emrosi for the U.S. market and expects that initial supply will be available late in the first quarter or early in the second quarter of 2025. Journey Medical plans to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.